How much does HIBRUKA (Orelabrutinib Tablets) Cost& price without insurance in China?
HIBRUKA® is the international commercial brand name of Orelabrutinib Tablets, an orally active, irreversible Bruton’s tyrosine kinase (BTK) inhibitor developed by Innocare. It covalently binds to BTK, inhibiting B-cell receptor signaling and thereby suppressing the proliferation and survival of malignant B cells.
Main Indications
Treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy.
Treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least one prior therapy.
Common Side Effects
Common mild adverse reactions: Neutropenia, thrombocytopenia, anemia, diarrhea, fatigue, and upper respiratory tract infections.
Laboratory abnormalities: Decreased white blood cell count, decreased platelet count, and decreased hemoglobin.
Severe but uncommon risks: Severe infections (including pneumonia and sepsis), hemorrhage events, atrial fibrillation/flutter, and second primary malignancies.
Approval Status in China
The drug is marketed in China under the brand name Yinuokai®. Orelabrutinib Tablets (50mg) were officially approved for marketing in China in 2020. It is currently a prescription anti-tumor drug included in China’s National Medical Insurance List.
Buy HIBRUKA (Orelabrutinib Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
